Phase II Trial of Irinotecan in Patients With Advanced Metastatic Breast Cancer Who Have Experienced Failure of an Anthracycline, a Taxane, and Capecitabine
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
To evaluate the safety and efficacy of Irinotecan in refractory breast cancer.
Pfizer CT.gov Call Center
Study Director
Pfizer
United States: Food and Drug Administration
CPTAPO-0047-146
NCT00072852
November 2003
May 2007
Name | Location |
---|---|
Pfizer Investigational Site | Birmingham, Alabama 35205 |
Pfizer Investigational Site | Detroit, Michigan 48201 |
Pfizer Investigational Site | Cincinnait, Ohio 45236 |
Pfizer Investigational Site | Springfield, Illinois 62701-1014 |
Pfizer Investigational Site | Bronx, New York 10461 |
Pfizer Investigational Site | Houston, Texas 77030 |
Pfizer Investigational Site | Federal Way, Washington 98003 |
Pfizer Investigational Site | Carmel, Indiana 46032 |
Pfizer Investigational Site | Kansas City, Kansas 66112 |
Pfizer Investigational Site | North Adams, Massachusetts 01247 |
Pfizer Investigational Site | Columbia, Missouri 65201 |
Pfizer Investigational Site | Bartlesville, Oklahoma 74006 |
Pfizer Investigational Site | Easley,, South Carolina 29640 |
Pfizer Investigational Site | Shreveport, Louisiana 71103 |
Pfizer Investigational Site | Milwaukee, Wisconsin 53215 |
Pfizer Investigational Site | Bristol, Tennessee 37620 |
Pfizer Investigational Site | Olive Branch, Mississippi 38654 |
Pfizer Investigational Site | Livingston, New Jersey 07039 |
Pfizer Investigational Site | Anchorage, Alaska 99508 |
Pfizer Investigational Site | Lewistown, Idaho 83501 |